The antiviral drug Paxlovid appears to reduce the risk of dying from COVID-19 by 79% and decrease hospitalizations by 73% in at-risk patients who are ages 65 and older, according to a new study.
, received FDA emergency use authorization in December 2021 to treat mild to moderate disease in ages 12 and older who face high risks for having severe COVID-19, hospitalization, and death.
Netzer and colleagues looked at hospitalization and death data for at-risk COVID-19 patients ages 40 and older between Jan. 9 and March 31, when the original Omicron variant was the dominant strain in Israel. During that time, more than 1.1 million Clalit patients were infected with COVID-19, 109,000 patients were considered at-risk, and 3,900 patients received the drug.
Among ages 65 and older, there were two deaths from COVID-19 in 2,484 treated patients, as compared with 158 in the 40,337 untreated patients. This represented a 79% lower chance of dying from COVID-19.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
COVID Antivirals Like Paxlovid ‘Vastly Underused' During Pandemic, Study SaysDespite clinical trials showing that it could significantly reduce the risk of death in COVID patients, studies have shown that antivirals like Paxlovid are being “vastly underused” during the pandemic.
Leer más »
Paxlovid, Pfizer's COVID pill, showed no measurable benefit in adults 40 to 65, study saysPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Leer más »
Pfizer COVID Pill Helped High-Risk Seniors But Showed No Benefit in Younger Adults: StudyThe findings reflect the changing nature of the pandemic, in which the vast majority of people already have some protection against the virus due to vaccination or prior infection
Leer más »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Leer más »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults.
Leer más »
Long COVID in Children Appears Less Common Than Early Fears SuggestedAlthough the risk of long COVID is not insignificant, it is much lower than previously thought
Leer más »